clioquinol
Trade name: nystaform
Approved
Jun 1, 1969
Clioquinol is a broad-spectrum antibacterial with antifungal properties, bacteriostatic. It is used as an antifungal and antiprotozoal topical drug OTC product for treatment of human infections. Previousely was used for wide number of intestinal disorders including lambliasis, shigellosis, balantidiral dysentery and some forms of diarrheas. The physiologic effect of clioquinol is by increased histamine release and cell-mediated immunity. It is a member of a family hydroxyquinolines which inhibit certain enzymes related to DNA replication. It is a copper, iron and zink chelating agent. It is an organic molecule with a quinolinic acid as its apparent core which itself is a neurotransmitter. In large doses it possesses neurotoxicity and may induce neurological disease such as subacute myelo-optic neuropathy by creating copper deficiency that leads to zink excess. SMON (Sub-Acute-Myelo-Optical-Neuropathy) - a polio-like disease began as an epidemic in 1959 in Japan was believed to be a Clioquinol caused. Clioquinol is a standardized chemical allergen. It has been resurrected as a potential treatment for Alzheimer's disease since it perturbs metallo-chemistry of amyloid and clioquinol treatment has been shown to be beneficial in a mouse model of Alzheimer's disease. — NCATS
Clinical trial activity
2 trials · 3 clinical orgs · 1 marketing orgs
Earliest trial started Aug 1, 2009 (NCT00963495)
Timeline
Indications
Approved for
Mechanism of action
- IronCHELATING AGENT
Iron chelating agent
Used as antibiotic against diarrhea in the 70s, but nowadays considered in cancer treatments (off-label), for its chelator and ionophore properties with capacity to inhibit proteosome
- CopperCHELATING AGENT
Copper chelating agent
Used as antibiotic against diarrhea in the 70s, but nowadays considered in cancer treatments (off-label), for its chelator and ionophore properties with capacity to inhibit proteosome
- ZincCHELATING AGENT
Zinc chelating agent
Used as antibiotic against diarrhea in the 70s, but nowadays considered in cancer treatments (off-label), for its chelator and ionophore properties with capacity to inhibit proteosome
Combination products
nystaform
with nystatin
Approval history
- approvedJun 1, 1969
Chemistry & pharmacology
SMILES
OC1=C2N=CC=CC2=C(Cl)C=C1I- Mol. weight
- 305.5 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaClioquinol ↗
- NCATS7BHQ856EJ5 ↗
- ChEMBLCHEMBL497 ↗
- ChEMBLCHEMBL2105605 ↗
Also known as
- 5-chlor-7-jod-8-hydroxy-chinolin
- 5-chlor-7-jod-8-hydroxy-chinolin
- 5-chloro-7-iodo-8-hydroxyquinoline
- 5-chloro-7-iodo-8-hydroxyquinoline
- 5-chloro-7-iodo-8-quinolinol
- 5-chloro-7-iodo-8-quinolinol
- 5-chloro-7-iodoquinolin-8-ol
- 5-chloro-7-iodoquinolin-8-ol
- 5-chloro-8-hydroxy-7-iodoquinoline
- 5-chloro-8-hydroxy-7-iodoquinoline
- 7-iodo-5-chloro-8-hydroxyquinoline
- 7-iodo-5-chloro-8-hydroxyquinoline
- 7-iodo-5-chloroxine
- 7-iodo-5-chloroxine
- chloroiodoquin
- chloroiodoquin
- chloroiodoquin
- chloroiodoquine
- cleoquinol
- clioquinol
- clioquinol
- clioquinol
- clioquinol
- clioquinol
- clioquinol
- clioquinol
- clioquinol
- clioquinol
- clioquinol
- clioquinolum
- clioquinolum
- cliquinol
- domeform-hc
- domeform-hc
- iodochlorhydroxyquin
- iodochlorhydroxyquin
- iodochlorhydroxyquin
- iodochlorhydroxyquin
- iodochlorhydroxyquinoline
- iodochlorhydroxyquinoline
- iodochlorohydroxyquin
- iodochlorohydroxyquin
- iodochloroxyquinoline
- iodochloroxyquinoline
- nystaform
- nystaform
- oralcer
- oralcer
- quin-o-creme
- quin-o-creme
- vioform
- vioform
- vioform
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01429701 | Phase 3 | May 1, 2012 | EMS S/A, Medicin Instituto da Pele |
| NCT00963495 | Phase 1 | Aug 1, 2009 | University of Toronto |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EMS S/A | For profit | 1 | 1 | 1 | 2012 |
| Medicin Instituto da Pele | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2009 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bayer | For profit | NDA | — |